EU's CHMP recommends NeurogesX's Qutenza for non-diabetic neuropathic pain
This article was originally published in Scrip
Executive Summary
NeurogesX's analgesic Qutenza (capsaicin) has received a positive opinion from the EU's CHMP for the treatment of neuropathic pain in non-diabetic adults, either as monotherapy, or as an adjunct to other analgesics.